Scancell Holdings Plc Notice of Interim Results and Presentation
26 January 2024 - 6:00PM
RNS Regulatory News
RNS Number : 9763A
Scancell Holdings Plc
26 January 2024
26 January 2024
Scancell Holdings plc
("Scancell" or the
"Company")
Notice of Interim Results and
Presentation
Scancell Holdings plc (AIM: SCLP), the
developer of novel immunotherapies for the treatment of cancer and
infectious disease, will announce its interim results for the six
months ended 31 October 2023 on Tuesday 30 January 2024.
Professor Lindy Durrant, Chief Executive
Officer, and Sath Nirmalananthan, Chief Financial Officer, will
host a live webcast and Q&A session for analysts and investors
at 14:00 GMT. If you would like to join the webcast,
please follow this link:
https://www.lsegissuerservices.com/spark/ScancellHoldings/events/f581274b-146c-4a89-af15-05bcae874775
A replay of the webcast will be made available
shortly afterwards.
Please contact ICR Consilium for further
details.
A copy of the presentation will also
be made available on the Company's news section
following the presentation.
-ENDS-
|
For further
information, please contact:
|
|
|
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive
Chairman
|
|
|
Stifel Nicolaus
Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
|
|
|
Nick Adams/Nick Harland (Corporate Broking)
|
|
|
WG Partners
LLP (Joint Broker)
David Wilson/Claes Spang/Sathesh Nadarajah/Erland
Sternby
|
+44 (0) 20 3705 9330
|
|
Panmure Gordon (UK)
Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate Finance)
|
|
|
Rupert Dearden (Corporate Broking)
|
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope®
and ImmunoBody®
for vaccines and GlyMab® and
AvidiMab® for
antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab®) or
enhances the potency of antibodies and their ability to directly
kill tumour cells
(AvidiMab®).
For further information about Scancell, please
visit: https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORVELFLZFLBBBF
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024
